• Smo in Honeybees Links Hedgehog Signaling to Olfaction

  2026-09-29

  Guo and colleagues identify and functionally examine Smoothened (Smo) in Apis mellifera, showing that Smo expression is enriched in antennae and associated with olfactory receptor expression, antennal electrophysiology, and odor-guided behavior. The study extends Hedgehog pathway research into insect sensory biology and provides a pharmacological framework for testing how Smo influences olfactory recognition.

• CHIR 99021 Trihydrochloride for Organoids

  2026-09-29

  Use CHIR 99021 trihydrochloride as a tunable GSK-3 inhibitor to interrogate stem-cell self-renewal, organoid diversification, and insulin-linked biology. This workflow separates concentration, exposure time, and differentiation context so researchers can distinguish pathway activation from nonspecific growth effects.

• Salinomycin for Reliable HCC Cell Assays

  2026-09-28

  This scenario-driven guide explains how Salinomycin (SKU A3785) can support better-designed viability, proliferation, apoptosis, and mechanism-focused assays in hepatocellular carcinoma research. It connects practical solvent and endpoint decisions with published guidance distinguishing relative from fractional viability.

• SGK1, Endothelial Mechanics, and Translation

  2026-09-28

  Endothelial SGK1 connects salt and mineralocorticoid signaling to vascular stiffness through changes in actin organization. This article interprets the mechanistic evidence, explains how EMD638683 can support pathway-focused experiments, and outlines practical controls for translational researchers—without confusing preclinical findings with clinical proof.

• NAT1–ENO1–Lactate Signaling in Colorectal Cancer

  2026-09-27

  A 2026 study identifies NAT1 as a metabolic regulator that restrains ENO1 and lactate production, linking glycolysis to TRAF6-dependent stabilization of PD-L1 in colorectal cancer. Its findings connect tumor metabolism with immune escape and suggest a mechanistic basis for testing interventions along the NAT1–ENO1–lactate axis, while leaving important questions about clinical translation open.

• LGK-974 Beyond Cancer: PORCN in Bone Disease

  2026-09-26

  LGK-974 is a potent PORCN inhibitor for investigating Wnt-dependent biology beyond cancer. This article examines how a 2025 sclerosteosis study translates upstream Wnt blockade into bone research, and what its findings mean for assay design and interpretation.

• Torin2 Workflows for mTOR Cancer Research

  2026-09-25

  Torin2 offers potent mTOR inhibition for pathway studies, viability and migration assays, and preclinical cancer research. This guide pairs practical handling and assay controls with a careful interpretation of a new cell-death finding: Pol II degradation can activate death independently of transcription loss, but that does not establish a shared mechanism with mTOR inhibition.

• Tankyrase Inhibition Restrains HCC Through Hippo Signaling

  2026-09-25

  Jia et al. report that XAV-939 and G007-LK suppress growth in human hepatocellular carcinoma (HCC) cell models while reducing YAP activity and increasing the negative regulators AMOTL1 and AMOTL2. The study links tankyrase inhibition to Hippo-pathway regulation and offers a mechanistic basis for testing this strategy in liver cancer models, while leaving its clinical relevance and in vivo efficacy unresolved.

• Wnt agonist 1: Workflows for Wnt Pathway Studies

  2026-09-24

  Use Wnt agonist 1 (BML-284) to probe β-catenin-dependent transcription and connect pathway activation to differentiation or cancer-cell phenotypes. This workflow pairs dose-and-time optimization with orthogonal readouts, including a carefully bounded approach to investigating the Wnt/NR2F2/GPX4 axis reported in lung cancer brain metastasis.

• GSK 2837808A in Lactate-Pathway Research

  2026-09-24

  Use GSK 2837808A to test whether LDHA-dependent lactate production drives metabolic phenotypes in cancer cells, with practical readouts that distinguish lactate changes from general loss of viability. Its established hepatocellular carcinoma context makes it a useful starting point for carefully bounded, hypothesis-generating studies of the NAT1–ENO1–lactate pathway in colorectal cancer.

• Anlotinib Suppresses Angiogenic Receptor Signaling

  2026-09-23

  The 2018 study examined how anlotinib limits angiogenesis induced by VEGF, PDGF-BB, and FGF-2, linking functional effects in endothelial and tissue-based assays to inhibition of VEGFR2, PDGFRβ, FGFR1, and ERK signaling. Its multi-model design supports further investigation of anlotinib as an anti-angiogenic research tool, while leaving clinical efficacy and the relative contribution of each target open for study.

• AG-221 Enasidenib Workflow for IDH2 AML

  2026-09-23

  Use AG-221 (Enasidenib) to connect mutant IDH2 activity with 2-hydroxyglutarate reduction, leukemia cell differentiation, and metabolic rewiring in controlled AML experiments. This workflow combines genotype-matched controls, metabolite analysis, and CD44-focused follow-up assays to distinguish on-target biology from nonspecific toxicity.

• CKI 7 Dihydrochloride: CK1 Inhibitor Guide

  2026-09-22

  CKI 7 dihydrochloride is a Casein kinase 1 inhibitor used to investigate ATP-dependent CK1 phosphorylation in Wnt, circadian, DNA-repair, and cancer models. It is a research reagent, not a validated inhibitor of the MAPK10–KRT16 axis described in recent NSCLC research.

• IWR-1-endo for Wnt-Driven Assay Design

  2026-09-22

  IWR-1-endo provides a mechanism-led way to suppress β-catenin accumulation in colorectal cancer, regenerative, and exploratory cardiomyocyte phenotyping workflows. Its Axin-dependent action can complement high-content morphological profiling by separating Wnt-responsive phenotypes from pathway-independent changes.

• GSK-923295: Reliable Mitosis Assay Design

  2026-09-21

  This scenario-driven guide explains how GSK-923295, SKU A3450, can improve interpretation of cell-growth, viability, and mitotic phenotypes. It connects CENP-E biology with formulation, dose planning, microscopy, vendor selection, and translational limits.

7903 records 1/527 page Next 12345 下5页 Last page